Higher prevalence of QTc interval prolongation among virologically suppressed older people with HIV
- PMID: 35969211
- DOI: 10.1097/QAD.0000000000003358
Higher prevalence of QTc interval prolongation among virologically suppressed older people with HIV
Abstract
Objective: To assess the prevalence, and factors associated with QTc interval prolongation, among 383 virologically suppressed people with HIV (PWH), without evidence of cardiovascular disease and active opportunistic infections in Thailand.
Design: Cross-sectional study.
Methods: Resting 12-lead digital ECGs were performed in 2019. QT interval corrected for heart rate (QTc) >450 ms in males and >460 ms in females was defined as QTc interval prolongation. We used multivariable logistic regression to investigate factors associated with QTc interval prolongation.
Results: Mean (standard deviation) age was 56 (5.5) years and 42% were female. The median current CD4+ was 619 (interquartile range [IQR] 487, 769) cells/mm 3 . The median duration of antiretroviral therapy (ART) was 11.9 (IQR 7.1-16.1) years. Commonly used ART were rilpivirine (37.9%), efavirenz (20.1%), atazanavir/ritonavir (15.7%), lopinavir/ritonavir (12.3%) and dolutegravir (5%). The prevalence of QTc interval prolongation was 22.7%. In multivariable analysis, older age (odds ratio [OR] 1.07, 95% confidence interval [CI] 1.02-1.12, P = 0.005), female sex (OR 1.69, 95% CI 1.01-2.82, P = 0.046) and increasing BMI (OR 1.08, 95% CI 1.01-1.15, P = 0.03) were associated with QTc interval prolongation. With every 1-year increase in age, the odds of QTc interval prolongation increased by 7%.
Conclusions: In this well-suppressed aging Asian HIV cohort, the prevalence of QTc interval prolongation was relatively high, and associated with increasing age, female sex, and higher BMI. For PLWH with these characteristics, QTc interval should be monitored before and after initiating any medications known to prolong QTc intervals, to prevent fatal cardiac arrhythmias.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Kearns A, Gordon J, Burdo TH, Qin X. HIV-1-associated atherosclerosis: unraveling the missing link . J Am Coll Cardiol 2017; 69:3084–3098.
-
- Tumkosit M, Han WM, Tankittiwat K, Chattranukulchai P, Siwamogsatham S, Apornpong T, et al. Higher epicardial fat in older adults living with HIV with viral suppression and relationship with liver steatosis, coronary calcium and cardiometabolic risks . AIDS 2022; 36:1073–1081.
-
- Chinello P, Lisena FP, Angeletti C, Boumis E, Papetti F, Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients . J Infect 2007; 54:597–602.
-
- Shavadia J, Shah R, Yonga G, Patel R, Stebbing J, Nelson M. The influence of antiretroviral therapy on the QTc interval in an African cohort . Clin Infect Dis 2012; 54:448–449.
-
- Moreno T, Perez I, Isasti G, Cabrera F, Santos J, Palacios R. Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients . AIDS Res Hum Retroviruses 2013; 29:1195–1198.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
